Recipharm’s Investment Enhances Efficiency & Speed for Customers & Patients

Recipharm recently announced a significant investment in its Oral Solid Development and Pilot Scale Centre in Zwickau, Germany. The investment includes three new GMP Pilot Scale suites for blending, tableting and hard capsule filling, which will complement the existing GMP pilot scale capabilities in dry granulation and wet granulation and related tools for material characterisation and material science.

The investment includes:

• A pilot scale hard capsule filler with dual filling and mini tablet dosing capabilities
• A Style One EVO Compression and Compaction Simulator, which complements the existing pilot scale dry granulation and tableting capabilities
• A pilot scale tablet press.

The new pilot scale centre for dry technologies will be GMP-ready by Q1 2025. This goes hand in hand with ReciPredict – an innovative combination and systematic application of material sciences, statistical tools and simulation. ReciPredict promises to deliver unparalleled efficiency and reliability to the pharmaceutical industry, by streamlining the product development cycle, from initial formulation through to manufacturing.

Dr. Uwe Hanenberg, PhD, Head of Product Implementation, said “With these advancements, we can now offer late-stage product development, clinical supply and commercial manufacturing from a single site. This integration makes it more efficient and cost-effective for our customers, providing them with access to top experts, while ensuring efficiencies in material consumption, including APIs. With our investment in ReciPredict as well as the GMP pilot scale for dry granulation and now the pilot scale for dry technologies, we have the tools and equipment at hand to support our custom with a faster clinic-to-market timeline for new drugs and de-risking manufacturing, ensuring greater certainty in meeting customer needs.”

With its new capabilities Recipharm in Zwickau is the ideal partner for API and excipient characterisation, product and process development, clinical Phase 2 and Phase 3 supply, small scale batch manufacturing, scale up and tech transfers, product optimisation and life cycle management.

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,200 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden. For more information, visit www.recipharm.com and www.recibiopharm.com